{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:24:35Z","timestamp":1789615475092,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.cllc.2017.01.013","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T05:21:04Z","timestamp":1486617664000},"page":"354-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pulsatile Erlotinib in EGFR-Positive Non\u2013Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review\u00a0of\u00a0the Literature"],"prefix":"10.1016","volume":"18","author":[{"given":"Joan","family":"How","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Laczniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Q.","family":"Baggstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2017.01.013_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.lungcan.2008.08.012","article-title":"Risk of cerebral metastases for postoperative locally advanced non\u2013small-cell lung cancer","volume":"64","author":"Wang","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib3","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/cncr.30000","article-title":"Risk of brain metastases in patients with nonmetastatic lung cancer: analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data","volume":"122","author":"Goncalves","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib4","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-010-0831-x","article-title":"Prognostic factors and treatment options in patients with leptomeningeal metastases of different\u00a0primary tumors: a retrospective analysis","volume":"136","author":"Oechsle","year":"2010","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib5","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.cllc.2017.01.013_bib6","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/modpathol.3801018","article-title":"Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond","volume":"21","author":"Ladanyi","year":"2008","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cllc.2017.01.013_bib7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non\u2013small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non\u2013small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2013.08.016","article-title":"Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma","volume":"82","author":"Iuchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib10","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2017.01.013_bib11","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.1158\/1078-0432.CCR-10-1588","article-title":"Development of central nervous system metastases in patients with advanced non\u2013small-cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib","volume":"16","author":"Heon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.01.013_bib12","doi-asserted-by":"crossref","first-page":"81906","DOI":"10.18632\/oncotarget.11918","article-title":"Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma","volume":"7","author":"Ma","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cllc.2017.01.013_bib13","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","article-title":"Response and resistance in a non\u2013small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib","volume":"24","author":"Jackman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11060-010-0128-6","article-title":"High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer","volume":"99","author":"Clarke","year":"2010","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cncr.22088","article-title":"A\u00a0phase I\/II study of weekly high-dose erlotinib in previously treated patients with non\u2013small-cell lung cancer","volume":"107","author":"Milton","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","article-title":"Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non\u2013small-cell lung cancer","volume":"31","author":"Welsh","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib17","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/neuonc\/noq076","article-title":"EGFR mutation status and survival after diagnosis of brain metastasis in non\u2013small-cell lung cancer","volume":"12","author":"Eichler","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0936-6555(05)80717-4","article-title":"Final results of the Royal College of Radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases","volume":"8","author":"Priestman","year":"1996","journal-title":"Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2017.01.013_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral\u00a0metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","volume":"31","author":"Soffietti","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.canlet.2014.04.019","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non\u2013small-cell lung cancer","volume":"351","author":"Zhang","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cllc.2017.01.013_bib23","first-page":"5797","article-title":"Brain metastases in NSCLC - are TKIs changing the treatment strategy?","volume":"35","author":"Dempke","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cllc.2017.01.013_bib24","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1158\/1078-0432.CCR-11-2529","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non\u2013small-cell lung cancer metastatic to the brain","volume":"18","author":"Jamal-Hanjani","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2017.01.013_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.lungcan.2008.12.011","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung\u00a0having asymptomatic synchronous brain metastasis","volume":"65","author":"Kim","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib26","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1183\/09031936.00195609","article-title":"Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation","volume":"37","author":"Porta","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cllc.2017.01.013_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.lungcan.2012.05.092","article-title":"Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non\u2013small-cell lung cancer patients harboring either exon 19 or 21 mutation","volume":"77","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib28","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/annonc\/mds529","article-title":"Erlotinib as second-line treatment in patients with advanced non\u2013small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803)","volume":"24","author":"Wu","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.21037\/jtd.2016.05.70","article-title":"Icotinib combined whole brain radiotherapy for patients with brain metastasis from lung adenocarcinoma harboring epidermal growth factor receptor mutation","volume":"8","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2017.01.013_bib30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/annonc\/mdh276","article-title":"Gefitinib in patients with brain metastases from non\u2013small-cell lung cancer: a prospective trial","volume":"15","author":"Ceresoli","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.lungcan.2004.04.036","article-title":"Effect of gefitinib (\u2018Iressa,\u2019 ZD1839) on brain metastases in patients with advanced non\u2013small-cell lung cancer","volume":"46","author":"Hotta","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3816\/CLC.2004.n.026","article-title":"Gefitinib in patients with brain metastases from non\u2013small-cell lung cancer: review of 15 clinical cases","volume":"6","author":"Namba","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.lungcan.2004.05.014","article-title":"Gefitinib is active in patients with brain metastases from non\u2013small-cell lung cancer and response is related to skin toxicity","volume":"47","author":"Chiu","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.lungcan.2007.03.011","article-title":"Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain","volume":"57","author":"Wu","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib35","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/COC.0b013e3182438c91","article-title":"The effectiveness of erlotinib against brain metastases in non\u2013small-cell lung cancer patients","volume":"36","author":"Bai","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib36","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jocn.2013.05.022","article-title":"Gefitinib and erlotinib for non\u2013small-cell lung cancer patients who fail to respond to radiotherapy for brain metastases","volume":"21","author":"Song","year":"2014","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.cllc.2017.01.013_bib37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non\u2013small-cell lung cancer patients with brain metastases or leptomeningeal disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jtho.2015.11.014","article-title":"First-line afatinib versus chemotherapy in patients with non\u2013small-cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases","volume":"11","author":"Schuler","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib39","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1016\/j.jtho.2016.11.514","article-title":"MA16.11 CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials","volume":"12","author":"Goss","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9003","article-title":"Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell-lung cancer (NSCLC) with\u00a0brain metastasis (BM) and leptomeningeal metastasis (LM)","volume":"34","author":"Ahn","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.lungcan.2015.06.001","article-title":"Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non\u2013small-cell lung cancer with sensitive EGFR mutations","volume":"89","author":"Gong","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib42","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9002","article-title":"Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non\u2013small-cell lung cancer (NSCLC): updated results from BLOOM, a phase I study","volume":"34","author":"Yang","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib43","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","article-title":"Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib","volume":"4","author":"Katayama","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib44","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2008.10.016","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non\u2013small-cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI","volume":"65","author":"Yi","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11523-014-0326-9","article-title":"Erlotinib in combination with pemetrexed\/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations\u00a0in lung adenocarcinoma patients after gefitinib faliure","volume":"10","author":"Yang","year":"2015","journal-title":"Target Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib46","doi-asserted-by":"crossref","first-page":"1241P","DOI":"10.1093\/annonc\/mdw383.41","article-title":"Afatinib efficacy and cerebrospinal fluid concentration in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis","volume":"27","author":"Tamiya","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib47","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.resinv.2016.04.001","article-title":"Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma","volume":"54","author":"Kanemaru","year":"2016","journal-title":"Respir Investig"},{"key":"10.1016\/j.cllc.2017.01.013_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijrobp.2014.02.022","article-title":"Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma","volume":"89","author":"Gerber","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2017.01.013_bib49","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","article-title":"A\u00a0phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non\u2013small-cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320","volume":"85","author":"Sperduto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2017.01.013_bib50","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2016.05.013","article-title":"EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases","volume":"11","author":"Jiang","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib51","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1038\/onc.2008.109","article-title":"BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2017.01.013_bib52","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib53","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1200\/JCO.2012.46.1764","article-title":"Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin\/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations","volume":"31","author":"Yang","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non\u2013small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2016.01.003","article-title":"Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non\u2013small-cell lung cancer","volume":"93","author":"Tan","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40261-016-0411-1","article-title":"Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non\u2013small-cell lung cancer","volume":"36","author":"Ricciuti","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cllc.2017.01.013_bib57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000446759","article-title":"Rapid intracranial response to osimertinib in a patient with epidermal growth factor receptor T790M-positive adenocarcinoma of the lung","volume":"39","author":"Reichegger","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.cllc.2017.01.013_bib58","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cllc.2017.01.013_bib59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2012.03.002","article-title":"Clinical outcome in patients with leptomeningeal metastasis from non\u2013small-cell lung cancer: Okayama Lung Cancer Study Group","volume":"77","author":"Umemura","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib60","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/JTO.0b013e3182398e4f","article-title":"Leptomeningeal metastasis from non\u2013small-cell lung cancer: survival and the impact of whole brain radiotherapy","volume":"7","author":"Morris","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib61","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.lungcan.2011.11.022","article-title":"Clinical outcomes of leptomeningeal metastasis in patients with non\u2013small-cell lung cancer in the modern chemotherapy era","volume":"76","author":"Park","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib62","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib63","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/JTO.0b013e318294c8e8","article-title":"Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non\u2013small-cell lung cancer","volume":"8","author":"Lee","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib64","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","article-title":"High incidence of disease recurrence in the brain and leptomeninges in patients with non\u2013small-cell lung carcinoma after response to gefitinib","volume":"103","author":"Omuro","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib66","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cncr.24877","article-title":"Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with non\u2013small-cell lung cancer","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib67","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1023\/A:1008318515795","article-title":"Chemotherapy for brain metastases of lung cancer: a review","volume":"10","author":"Postmus","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00280-007-0616-3","article-title":"The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates","volume":"62","author":"Meany","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2017.01.013_bib69","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/JTO.0b013e3181e2138b","article-title":"Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non\u2013small-cell lung cancer","volume":"5","author":"Togashi","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib70","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib71","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(03)70012-8","article-title":"Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva)","volume":"30","author":"Hidalgo","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-013-0058-5","article-title":"Population pharmacokinetics\/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non\u2013small-cell lung cancer","volume":"52","author":"Fukudo","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cllc.2017.01.013_bib74","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00280-011-1691-z","article-title":"Efficacy of increased-dose erlotinib for central nervous system metastases in non\u2013small-cell lung cancer patients with epidermal growth factor receptor mutation","volume":"68","author":"Togashi","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2017.01.013_bib75","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/1759-7714.12384","article-title":"Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non\u2013small-cell lung cancer patients with secondary drug resistance: a single center, single arm, phase II clinical trial","volume":"7","author":"Zhu","year":"2016","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib76","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1200\/JCO.2008.21.0963","article-title":"Carcinomatous meningitis in non\u2013small-cell lung cancer: response to high-dose erlotinib","volume":"27","author":"Dhruva","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib77","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"\u201cPulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non\u2013small-cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib78","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2012.12.024","article-title":"High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases\u2013one with a remarkable thoracic response as well","volume":"80","author":"Kuiper","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2017.01.013_bib79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.14740\/wjon859w","article-title":"Pulsed erlotinib as sole treatment of leptomeningeal carcinomatosis: can we avoid the use of intrathecal therapy?","volume":"5","author":"Santhosh-Kumar","year":"2014","journal-title":"World J Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib80","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000449405","article-title":"Rapid response to high-dose, pulsatile erlotinib in afatinib-refractory leptomeningeal carcinomatosis from adenocarcinoma of the lung: a case report","volume":"9","author":"Fan","year":"2016","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib81","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/JTO.0b013e3181d899bb","article-title":"High-dose erlotinib for refractory brain metastases in a patient with relapsed non\u2013small-cell lung cancer","volume":"6","author":"Hata","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2017.01.013_bib82","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00280-015-2759-y","article-title":"High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs","volume":"75","author":"Kawamura","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2017.01.013_bib83","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.resinv.2016.04.001","article-title":"Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma","volume":"54","author":"Kanemaru","year":"2016","journal-title":"Respir Investig"},{"key":"10.1016\/j.cllc.2017.01.013_bib84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2017.01.013_bib85","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non\u2013small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417300426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730417300426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:06:42Z","timestamp":1761505602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730417300426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1525730417300426"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2017.01.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulsatile Erlotinib in EGFR-Positive Non\u2013Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review\u00a0of\u00a0the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2017.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}